QTVLF News Alert Qt Vascular Ltd (QTVLF) 0.2400 02/15/2015 1
Post# of 64074
Posted On: 02/15/2015 11:06:08 AM
Qt Vascular Ltd (QTVLF) 0.2400 $QTVLF
QT Vascular Announces Acquisition of Novel Technology for Interventional Treatment
PR Newswire - Thu Oct 23, 10:05AM CDT
Catalist-listed QT Vascular Ltd. ("QT Vascular" or together with its subsidiaries, "the Group"
, a developer and manufacturer of minimally invasive medical devices for the treatment of vascular diseases, is pleased to announce that the Group has acquired a novel technology platform called Java, and all associated intellectual property, which was developed independently in Israel.
First European Patients Enrolled in QT Vascular's ENDURE Trial
PR Newswire - Mon Sep 15, 12:00PM CDT
Catalist-listed QT Vascular Ltd. ("QT Vascular" or together with its subsidiaries, "the Group" , a developer and manufacturer of minimally invasive medical devices for the treatment of vascular diseases, is pleased to announce that the Group has enrolled the first European patients in the ENDURE Trial in Germany. Multiple patients have already been enrolled in this study with Dr. Andrew Holden, at Auckland City Hospital, in Auckland, New Zealand.
QT Vascular Announces Acquisition of Novel Technology for Interventional Treatment
PR Newswire - Thu Oct 23, 10:05AM CDT
Catalist-listed QT Vascular Ltd. ("QT Vascular" or together with its subsidiaries, "the Group"
, a developer and manufacturer of minimally invasive medical devices for the treatment of vascular diseases, is pleased to announce that the Group has acquired a novel technology platform called Java, and all associated intellectual property, which was developed independently in Israel. First European Patients Enrolled in QT Vascular's ENDURE Trial
PR Newswire - Mon Sep 15, 12:00PM CDT
Catalist-listed QT Vascular Ltd. ("QT Vascular" or together with its subsidiaries, "the Group"
, a developer and manufacturer of minimally invasive medical devices for the treatment of vascular diseases, is pleased to announce that the Group has enrolled the first European patients in the ENDURE Trial in Germany. Multiple patients have already been enrolled in this study with Dr. Andrew Holden, at Auckland City Hospital, in Auckland, New Zealand. 
(0)
(0)Scroll down for more posts ▼